Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Oral Erlotinib Monotherapy in a Patient With EGFR-Negative Status in Histology and Progressive Disease on Conventional Chemotherapy.

Clinical nuclear medicine - 1 Nov 2021

Sharma Anshul, Kumar Rakesh

Abstract excerpt

ABSTRACT: An 80-year-old woman, presenting with weight loss and dyspnea for 8 months, showed bilateral lung consolidation in baseline 18F-FDG PET/CT and adenocarcinoma in bronchoscopy-guided biopsy. Epidermal growth factor receptor mutational status was negative in immunohistochemistry analysis, as well as in repeat liquid biopsy. When she developed progression on conventional chemotherapy, a trial of T....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Positron Emission Tomography Computed Tomography

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 34028410
DOI: 10.1097/RLU.0000000000003687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Oral Erlotinib Monotherapy in a Patient With EGFR-Negative Status in Histology and Progressive Disease on Conventional Chemotherapy.PMID 34028410Read ↗

Erlotinib in lung cancer.Semantic proximity Read ↗

Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung.Semantic proximity Read ↗

[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].Semantic proximity Read ↗

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.Semantic proximity Read ↗

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review.Semantic proximity Read ↗

Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.Semantic proximity Read ↗

Tuberculosis in epidermal growth factor receptor mutation in lung adenocarcinoma on treatment with gefitinib/erlotinib.Semantic proximity Read ↗

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.Semantic proximity Read ↗

Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.Semantic proximity Read ↗

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.Semantic proximity Read ↗

Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.